Dear Dr. Hoff:

Please refer to your supplemental new drug application submitted September 24, 2007, received September 24, 2007 under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Depakote ER (divalproex sodium extended-release tablets) 250 mg and 500 mg.


We have completed the review of this supplemental application, as amended, and it is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling, unless we notify you otherwise.

**PREA Requirements: Phase 4 Commitments for NDA 21-168/S-015.**

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred.

NDA 21-168/S-015 does not provide for any claims that would require further pediatric studies under PREA, nor are any other Phase 4 commitments required for this submission.

**Pediatric Research Equity Act (PREA) Fulfilled for NDA 21-168.**

Migraine

We have concluded that the pediatric study reports submitted under NDA 21-168/S-015 fulfill the pediatric study requirements for pediatric patients ages 12 to 17 described in our August 4, 2000 approval letter for NDA 21-168.
We also note that our August 4, 2000 approval letter for NDA 21-168 waived the pediatric study requirement for migraine headache prophylaxis in pediatric patients less than 12 years of age.

**Epilepsy**

We have concluded that the pediatric study reports submitted under NDA 21-168/S-015 fulfill the pediatric study requirements for pediatric epilepsy patients ages 3 up to 10 years that were required by the submission of NDA 21-168/S-004.

In addition, we are waiving the pediatric study requirement for epilepsy in pediatric patients less than 3 years of age. We note that the pediatric study requirements for pediatric epilepsy patients ages 10 to 16 years were previously fulfilled with the approval of NDA 21-168/S-007.

**Content of Labeling: Structured Product Labeling [SPL].** As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in Structured Product Labeling (SPL) format, as described at [http://www.fda.gov/oc/datacouncil/spl.html](http://www.fda.gov/oc/datacouncil/spl.html), that is identical to the enclosed agreed-upon labeling text. Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission "SPL for approved sNDA labeling under 21-168/S-015".

**Dear Healthcare Professional Letter.** If you issue a letter communicating important information about this product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to NDA 21-168, with a copy to the following address:

MEDWATCH, HFD-410
Food and Drug Administration
5901-B Ammendale Road
Beltsville, MD 20705-1266

**Reporting Requirements.** We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Jacqueline H. Ware, Pharm.D., Senior Regulatory Project Manager, at 301-796-1040.

Sincerely,

{see appended electronic signature page}

Russell Katz, M.D.
Director
Division of Neurology Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure: agreed-upon labeling.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------
Russell Katz
3/24/2008 06:23:02 PM